Hope S. Rugo, MD, FASCO

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Hope S. Rugo, MD, discusses the impact of margetuximab in patients with HER2-positive metastatic breast cancer who have an F allele versus V allele.

Hope S. Rugo, MD, discusses results of a randomized phase III trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

Hope S. Rugo, MD, discusses the rationale for the phase II ELAINE study with lasofoxifene in patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses unmet needs beyond second-line treatment in HER2+ breast cancer.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the regulatory process behind biosimilars in oncology.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, discusses the therapeutic advancements in the breast cancer space in the past 20 years.

Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Hellen Diller Family Comprehensive Cancer Center, discusses the results of the SWISH trial, which examined a dexamethasone-based mouthwash for the prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses a meta-analysis that examined how stomatitis impacts the efficacy of everolimus

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with metastatic breast cancer with chemotherapy.

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

Dr. Hope Rugo, from the UCSF Helen Diller Family Comprehensive Cancer Center, Examines Angiogenesis Inhibition Trials in Advanced Breast Cancer.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Hope S. Rugo from the University of California, San Francisco on the Efficacy of Bevacizumab in Breast Cancer

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. Hope S. Rugo from UCSF Cancer Center on the Future of Angiogenesis in Breast Cancer

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors